ebtreatmentreport.com valuation and analysis

Robots.txt Information
Robot Path Permission
GoogleBot /
BingBot /
BaiduSpider /
YandexBot /
Meta Tags
Title EB Treatment
Description www.EBTreatmentReport.com
Keywords N/A
Server Information
WebSite ebtreatmentreport faviconebtreatmentreport.com
Host IP 34.73.45.65
Location United States
Related Websites
Site Rank
More to Explore
ebtreatmentreport.com Valuation
US$910
Last updated: 2023-05-02 17:41:22

ebtreatmentreport.com has Semrush global rank of 0. ebtreatmentreport.com has an estimated worth of US$ 910, based on its estimated Ads revenue. ebtreatmentreport.com receives approximately 105 unique visitors each day. Its web server is located in United States, with IP address 34.73.45.65. According to SiteAdvisor, ebtreatmentreport.com is safe to visit.

Traffic & Worth Estimates
Purchase/Sale Value US$910
Daily Ads Revenue US$0
Monthly Ads Revenue US$25
Yearly Ads Revenue US$302
Daily Unique Visitors 7
Note: All traffic and earnings values are estimates.
DNS Records
Host Type TTL Data
ebtreatmentreport.com. A 3599 IP: 34.73.45.65
ebtreatmentreport.com. NS 3600 NS Record: ns20.domaincontrol.com.
ebtreatmentreport.com. NS 3600 NS Record: ns19.domaincontrol.com.
HtmlToTextCheckTime:2023-05-02 17:41:22
EB Treatment Report www.EBTreatmentReport.com This page tracks new and upcoming treatment options for epidermolysis bullosa (EB). What’s in development? What’s promising? What’s available soon? Current topics include AP103, gene therapy, EB-101, Filsuvez, AGLE-102, stem cells, B-VEC, KB-103, PTR-01, QR-313, FCX-007, INM-755, and more. Jump to section: News , Research , Clinical Trials , Projects Last updated: 3 years ago Subscribe News Aegle Therapeutics Receives Rare Pediatric Disease Designation from FDA for AGLE-102 for Patients with Dystrophic Epidermolysis Bullosa Oct 6, 2020 Orphan Drug Status in Europe Likely for AP103, DEB Gene Therapy Sep 30, 2020 A new approach to understanding the biology of wound healing Sep 15, 2020 Positive Opinion from EMA on Orphan Drug Designation for Amryt’s RDEB Gene Therapy Candidate, AP103 Sep 15, 2020 Amryt Eyes Approval for Epidermolysis Bullosa Drug Following Phase III Data Sep 9, 2020 Amryt Announces Positive Top Line Results from Pivotal
HTTP Headers
HTTP/1.1 301 Moved Permanently
Server: nginx
Date: Mon, 25 Oct 2021 02:36:13 GMT
Content-Type: text/html
Content-Length: 162
Connection: keep-alive
Keep-Alive: timeout=20
Location: http://www.ebtreatmentreport.com/

HTTP/1.1 301 Moved Permanently
Server: nginx
Date: Mon, 25 Oct 2021 02:36:14 GMT
Content-Type: text/html
Content-Length: 162
Connection: keep-alive
Keep-Alive: timeout=20
Location: https://www.ebtreatmentreport.com/

HTTP/2 200 
server: nginx
date: Mon, 25 Oct 2021 02:36:14 GMT
content-type: text/html; charset=UTF-8
content-length: 76094
vary: Accept-Encoding
vary: Accept-Encoding
link: ; rel="https://api.w.org/"
link: ; rel="alternate"; type="application/json"
link: ; rel=shortlink
x-powered-by: WP Engine
x-cacheable: SHORT
vary: Accept-Encoding,Cookie
cache-control: max-age=600, must-revalidate
x-cache: HIT: 1
x-cache-group: normal
accept-ranges: bytes
ebtreatmentreport.com Whois Information
Domain Name: EBTREATMENTREPORT.COM
Registry Domain ID: 2503850114_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.godaddy.com
Registrar URL: http://www.godaddy.com
Updated Date: 2021-03-16T16:47:52Z
Creation Date: 2020-03-15T22:43:31Z
Registry Expiry Date: 2022-03-15T22:43:31Z
Registrar: GoDaddy.com, LLC
Registrar IANA ID: 146
Registrar Abuse Contact Email: abuse@godaddy.com
Registrar Abuse Contact Phone: 480-624-2505
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS19.DOMAINCONTROL.COM
Name Server: NS20.DOMAINCONTROL.COM
DNSSEC: unsigned
>>> Last update of whois database: 2021-09-13T07:34:00Z <<<